![COVID-19 outpatients – early risk-stratified treatment with zinc plus low dose hydroxychloroquine and azithromycin: a retrospective case series study – ScienceOpen COVID-19 outpatients – early risk-stratified treatment with zinc plus low dose hydroxychloroquine and azithromycin: a retrospective case series study – ScienceOpen](https://www.scienceopen.com/document_file/d6cfd583-9643-4de4-9962-e5d67ff05418/PubMedCentral/large.png)
COVID-19 outpatients – early risk-stratified treatment with zinc plus low dose hydroxychloroquine and azithromycin: a retrospective case series study – ScienceOpen
![Pharmacokinetics and Pharmacodynamics of Intravenous and Oral Azithromycin: Enhanced Tissue Activity and Minimal Drug Interactions | Semantic Scholar Pharmacokinetics and Pharmacodynamics of Intravenous and Oral Azithromycin: Enhanced Tissue Activity and Minimal Drug Interactions | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/ea131fb07093200050732b8ec43240efe19ee6c5/3-Table2-1.png)
Pharmacokinetics and Pharmacodynamics of Intravenous and Oral Azithromycin: Enhanced Tissue Activity and Minimal Drug Interactions | Semantic Scholar
![COVID-19: Can early home treatment with Azithromycin alone or with Zinc help prevent hospitalisation, death, and long-COVID-19? A review | medRxiv COVID-19: Can early home treatment with Azithromycin alone or with Zinc help prevent hospitalisation, death, and long-COVID-19? A review | medRxiv](https://www.medrxiv.org/content/medrxiv/early/2021/01/04/2020.12.29.20248975/F2.large.jpg)
COVID-19: Can early home treatment with Azithromycin alone or with Zinc help prevent hospitalisation, death, and long-COVID-19? A review | medRxiv
![Double-blind, placebo-controlled, randomized trial on low-dose azithromycin prophylaxis in patients with primary antibody deficiencies - ScienceDirect Double-blind, placebo-controlled, randomized trial on low-dose azithromycin prophylaxis in patients with primary antibody deficiencies - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0091674919303884-fx1.jpg)
Double-blind, placebo-controlled, randomized trial on low-dose azithromycin prophylaxis in patients with primary antibody deficiencies - ScienceDirect
![Antibiotic Steward Bassam Ghanem🆔🌟 on Twitter: "⛔In a Sarcastic way ⛔ This study doesn't prove anything Hydroxychloroquine designed to be effective in #COVID19 patients only when you add Azithromycin and Zinc together. Antibiotic Steward Bassam Ghanem🆔🌟 on Twitter: "⛔In a Sarcastic way ⛔ This study doesn't prove anything Hydroxychloroquine designed to be effective in #COVID19 patients only when you add Azithromycin and Zinc together.](https://pbs.twimg.com/media/EhJWuQ-WAAAYgdq.jpg)
Antibiotic Steward Bassam Ghanem🆔🌟 on Twitter: "⛔In a Sarcastic way ⛔ This study doesn't prove anything Hydroxychloroquine designed to be effective in #COVID19 patients only when you add Azithromycin and Zinc together.
![Comparative efficacy of low-dose versus standard-dose azithromycin for patients with yaws: a randomised non-inferiority trial in Ghana and Papua New Guinea.,The Lancet - X-MOL Comparative efficacy of low-dose versus standard-dose azithromycin for patients with yaws: a randomised non-inferiority trial in Ghana and Papua New Guinea.,The Lancet - X-MOL](https://xpic.x-mol.com/20180312%2F10.1016_S2214-109X%2818%2930023-8.jpg)
Comparative efficacy of low-dose versus standard-dose azithromycin for patients with yaws: a randomised non-inferiority trial in Ghana and Papua New Guinea.,The Lancet - X-MOL
![Efficacy of azithromycin in severe asthma from the AMAZES randomised trial | European Respiratory Society Efficacy of azithromycin in severe asthma from the AMAZES randomised trial | European Respiratory Society](https://openres.ersjournals.com/content/erjor/5/4/00056-2019/F1.large.jpg)
Efficacy of azithromycin in severe asthma from the AMAZES randomised trial | European Respiratory Society
![Azithromycin for community treatment of suspected COVID-19 in people at increased risk of an adverse clinical course in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial - The Lancet Azithromycin for community treatment of suspected COVID-19 in people at increased risk of an adverse clinical course in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial - The Lancet](https://www.thelancet.com/cms/asset/2ffb2e5b-9e76-4765-a065-5fab6b80633d/gr1.jpg)